Evidence map›Paper›PMID 34900791›Full record

ArticleJournal of diabetes and metabolic disorders2021

A systematic review of miRNAs as biomarkers in osteoporosis disease.

Mandana Hasanzad, Maryam Hassani Doabsari, Marzieh Rahbaran, Pantea Banihashemi, Fatemeh Fazeli, Mehrnoush Ganji, Shahrzad Manavi Nameghi, Negar Sarhangi, Shekoufeh Nikfar, Hamid Reza Aghaei Meybodi

Open access · greenAbstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. The MicroRNAs in the Pathophysiology of Osteoporosis.International journal of molecular sciences · 2024
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mandana HasanzadMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.ORCID 0000-0002-0538-1135
Maryam Hassani DoabsariMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Marzieh RahbaranMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Pantea BanihashemiMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Fatemeh FazeliMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Mehrnoush GanjiMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Shahrzad Manavi NameghiMedical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Negar SarhangiPersonalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, No.10-Jalal-e-Ale-Ahmad Street, Chamran Highway, 1411713119 Tehran, Iran.ORCID 0000-0003-2385-7333
Shekoufeh NikfarPersonalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, No.10-Jalal-e-Ale-Ahmad Street, Chamran Highway, 1411713119 Tehran, Iran.ORCID 0000-0002-5206-6197
Hamid Reza Aghaei MeybodiPersonalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, No.10-Jalal-e-Ale-Ahmad Street, Chamran Highway, 1411713119 Tehran, Iran.ORCID 0000-0003-1754-3450
Islamic Azad University Medical Branch of Tehran · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteoporosis is often considered to be a disease of the elderly, which is characterized by two characteristics: low bone mineral density (BMD) and increased risk of fracture. MicroRNAs (miRNAs) have been reported to play a potential role in bone formation and resorption, bone remodeling, bone homeostasis regulation, and bone cell differentiation. Therefore, altered expression of different miRNAs may impact the pathology of bone diseases such as osteoporosis. A systematic review was conducted to extract all miRNA found to be significantly dys-regulated in the peripheral blood.

methodsThis review was carried out using a systematically search on PubMed, Scopus, Embase, Web of Science (WoS), and Cochrane databases from 1990 to 2018 to explore the diagnostic value of miRNAs as a biomarker in osteoporosis.

resultsA total of 31 studies were identified in the systematic review that indicated more than 30 kinds of up-regulated and down-regulated miRNAs in three categories; postmenopausal osteoporosis, postmenopausal osteoporosis with fracture risk, and other types of osteoporosis and fracture risk.

conclusionThe collective data presented in this review indicate that miRNAs could serve as biomarkers for the diagnosis (onset) and prognosis (progression of osteoporosis), while the clinical application of these findings has yet to be verified. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40200-021-00873-5.

Indexed as

BiomarkermiRNAOsteoporosis

Identifiers

PMID34900791
PMCPMC8630174
OpenAlexW3196715187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.